OTC · Biotechnology

Basilea Pharmaceutica AG (BPMUF) Stock

$60.28 +0.00% OTC: BPMUF Healthcare

Basilea Pharmaceutica AG is a biopharmaceutical company already generating revenue from its products, which are designed to fulfill medical needs in the challenging areas of cancer (oncology) and infectious diseases (anti-infectives). The company's product portfolio includes Cresemba, an azole antifungal drug administered intravenously or orally.

Valuation

MetricValue
Price$60.28
Market Cap$746.00M
P/E Ratio19.58
P/B Ratio4.95
P/S Ratio3.56
EPS (TTM)$3.08
52-Week High$74.00
52-Week Low$47.50
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE27.95%
ROA11.45%
ROCE17.00%
Gross Margin74.32%
Operating Margin21.94%
Net Margin17.90%
Debt/Equity0.70
Current Ratio5.11

Annual Financials (USD)

Metric20212022202320242025
Revenue$148.0M$148.0M$158.0M$209.0M$233.0M
Operating Profit$1.0M$19.0M$19.0M$61.0M$52.0M
Net Profit$-7.0M$12.0M$10.0M$78.0M$40.0M
EPS$-0.58$1.02$0.86$5.83$3.14
Op Margin0.8%12.6%12.2%29.3%22.2%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$247.0M$221.0M$173.0M$258.0M$282.0M
Total Liabilities$306.0M$266.0M$183.0M$177.0M$154.0M
Cash$54.0M$85.0M$60.0M$121.0M$30.0M
Borrowings$219.0M$187.0M$129.0M$112.0M$89.0M

Latest News

John Hussman's Top Q2 2026 Move: Exiting Corcept Therapeutics Inc at a -1.1% Portfolio Impact GuruFocus.com · Aug 4, 2026 Proposed ASMFC Menhaden Addendum Is a Solution Searching for a Problem ACCESS Newswire · Aug 4, 2026 A Major Bitcoin Signal Is Flashing Green Coinage Coop · Aug 4, 2026 ETF Inflows Hit $191B in July as 2026 Total Nears $1.3 Trillion etf.com · Aug 3, 2026 Freshworks (FRSH) To Report Earnings Tomorrow: Here Is What To Expect StockStory · Aug 3, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-32.0M$7.0M$14.0M$74.0M$62.0M
Investing Cash Flow$2.0M$88.0M$-2.0M$-3.0M$-5.0M
Financing Cash Flow$40.0M$-124.0M$0$0$0
Net Cash Flow$-11.0M$54.0M$-44.0M$60.0M$14.0M
Free Cash Flow$-33.0M$4.0M$13.0M$73.0M$59.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.35
EV / EBITDA16.75
FCF Yield7.49%
Quick Ratio4.68
Interest Coverage11.79
Return 1Y—
Return 3Y—
Return 5Y—

Ownership

Insiders Held0.62%
Institutions Held30.74%
Institutions Float Held30.93%
Institutional HolderSharesReport Date
American Century ETF Trust-Avantis International Small Cap Value ETF271,0662026-06-30
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund177,0712026-04-30
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund118,1392026-03-31
iShares Trust-iShares Core MSCI EAFE ETF112,9692026-06-30
iShares Trust-iShares MSCI EAFE Small-Cap ETF50,0212026-06-30

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
BJTRFBeijing Tong Ren Tang Chinese Medicine Company Limited $0.65 +0.00% 14.49 $542.78M 7.69%
FOGCFAvisa Diagnostics Inc. $0.00 — -0.23 $97176 0.00%
GSGTFGenSight Biologics S.A. $0.09 +0.00% -1.04 $14.67M 0.00%
INRLFValneva SE $2.43 -7.25% -2.67 $460.84M 0.00%
MDCLFMedinCell S.A. $34.39 +0.00% -27.12 $1.23B 0.00%

About Basilea Pharmaceutica AG

Basilea Pharmaceutica AG is a biopharmaceutical company already generating revenue from its products, which are designed to fulfill medical needs in the challenging areas of cancer (oncology) and infectious diseases (anti-infectives). The company's product portfolio includes Cresemba, an azole antifungal drug administered intravenously or orally. This medication is approved for treating invasive aspergillosis and mucormycosis in both the United States and the European Union. Additionally, Cresemba is undergoing Phase III clinical trials in Japan for addressing invasive fungal infections. Another key product is Zevtera, an antibiotic prescribed for both community-acquired and hospital-acquired pneumonia. This antibiotic is also advancing through Phase III clinical studies, investigating its effectiveness against acute bacterial skin and skin structure infections and Staphylococcus aureus bacteremia. In its development pipeline, Basilea is advancing Derazantinib, a small molecule inhibitor. This compound is currently in Phase 2 clinical trials for bile duct cancer and in Phase 1/2 trials for bladder and stomach cancers. The company is also developing Lisavanbulin, which acts as a tumor checkpoint controller drug. Founded in the year 2000, Basilea Pharmaceutica AG is based in Basel, Switzerland.

Basilea Pharmaceutica AG is headquartered in CH.

Basilea Pharmaceutica AG (BPMUF) stock trades at $60.28 with a market capitalization of $746.00M. The stock is valued at a price-to-earnings (P/E) ratio of 19.58, price-to-book of 4.95, price-to-sales of 3.56. Over the past 52 weeks the stock has ranged between $47.50 and $74.00, and currently trades 18.5% below its 52-week high.

On profitability, Basilea Pharmaceutica AG generates a return on equity (ROE) of 27.95% — well above the market average, a sign of a high-quality business, return on capital employed of 17.00%, an operating margin of 21.94%, a net profit margin of 17.90%.

Official website: www.basilea.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides